The potential of circulating microRNA (miRNA) levels as a biomarker in drug development: An analysis of tumor-serum samples from patients on a phase I trial of saracatinib-paclitaxel (P)-carboplatin (C).
D. S. Tan
No relevant relationships to disclose
S. Aamdal
No relevant relationships to disclose
G. Freyer
No relevant relationships to disclose
R. J. Jones
Consultant or Advisory Role - AstraZeneca
Honoraria - AstraZeneca
Research Funding - AstraZeneca
Other Remuneration - AstraZeneca
S. B. Kaye
Consultant or Advisory Role - AstraZeneca
Honoraria - AstraZeneca
E. Pujade-Lauraine
No relevant relationships to disclose
J. Fog
No relevant relationships to disclose
M. Wrang Teilum
No relevant relationships to disclose
C. Glue
No relevant relationships to disclose
A. Baker
No relevant relationships to disclose
U. A. Emeribe
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
P. Elvin
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
C. Stephens
Employment or Leadership Position - AstraZeneca
M. Stuart
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
J. Walker
Employment or Leadership Position - AstraZeneca
E. Boven
Research Funding - Roche